在儿童肿瘤学组标准风险B细胞急性淋巴细胞性白血病试验AALL1731中，患者出现了SARS-CoV-2感染。
SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731.
发表日期：2023 Aug
作者：
Caitlin W Elgarten, John A Kairalla, Joel C Thompson, Tamara P Miller, Cindy Wang, Susan Conway, Mignon L Loh, Elizabeth A Raetz, Sumit Gupta, Rachel E Rau, Anne Angiolillo, Karen R Rabin, Sarah Alexander
来源：
Cell Death & Disease
摘要：
血液系统恶性肿瘤是成人严重急性呼吸综合征冠状病毒2型（COVID-19）的危险因素，但关于白血病儿童的数据有限。本研究分析了持续进行中的儿童肿瘤学协作组（COG）标准风险B型急性淋巴细胞性白血病/淋巴瘤（ALL/LLy）试验AALL1731中高质量的传染性不良事件数据，以提供儿科ALL患者罹患SARS-CoV-2感染的疾病特异性估计。在253名报告感染的患者中，大部分（77.1%）无症状或症状轻微（CTCAE 1/2级），仅有一例与COVID-19相关的死亡病例。这些数据表明SARS-CoV-2感染在年轻的B淋巴母细胞性白血病/淋巴瘤（B-ALL/LLy）患者中并没有引起严重的发病率。© 2023 The Authors.eJHaem由英国血液学学会和John Wiley & Sons Ltd.出版。
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.